Ryan McBride

Communications leader helping the world understand biomedicine. Views here are my own.

[Ryan McBride @rymcbr]

It’s not only time to develop our a.i. chops, it’s time to think hard about what will be left for humans to do in few years. Read more from ⁦@WSJ⁩ https://t.co/DSvdeNn8Lz

[J&J Innovative Medicine @JNJInnovMed]

#NEWS: The FDA has approved our treatment for adults with moderately to severely active Crohn’s disease.

Learn more about what this means for the inflammatory bowel disease (IBD) community: https://t.co/fz9BGPPCiY

#JNJImmunology

[Ryan McBride @rymcbr]

@damiangarde Congrats, Damian!

[Ryan McBride @rymcbr]

Thanks to @edyong209 for speaking last night in Philly at our patient advocacy event #HealtheVoices22, and how appropriate on the heels of his sabbatical announcement for Ed to talk up curiosity, kindness and empathy—qualities to take care of others and ourselves.

[Ed Yong is not here @edyong209]

🧵Some personal news: I’m taking a 6-month sabbatical, starting now. These past 3 years have been the most professionally meaningful of my life, but they’ve also deeply broken me. The pandemic isn’t over, but after a long time spent staring into the sun, I need to blink. 1/

[Ryan McBride @rymcbr]

Our team is opening a state-of-the-art @JNJNews center today in the Bay Area—very exciting for our scientists, partners and other innovators. https://t.co/FLOvBYxBZq

[Hannah Kuchler @hannahkuchler]

J&J’s Najat Khan says we must adapt to do precision medicine clinical trials in the current system e.g. building an algorithm to understand tumor mutations from biopsies, because the vast majority of patients do not get their tumors sequenced. #FTpharma

[J&J Innovative Medicine @JNJInnovMed]

Vaccines have an unparalleled impact in helping people live longer lives and can prevent both infectious diseases and major health crises, including COVID-19 and Ebola. #WorldImmunizationWeek #LongLifeForAll

[J&J Innovative Medicine @JNJInnovMed]

At this year's @AACR Annual Meeting, we're sharing our latest advances in oncology as we aim to prevent, intercept and cure #cancer. #AACR22

https://t.co/NPMWAHo63R

[Dan Nomura @DanNomura]

The emerging role of mass spectrometry-based proteomics in drug discovery | Nature Reviews Drug Discovery https://t.co/9jaw7sE96C

[Reuters @Reuters]

J&J booster slashes Omicron hospitalizations -S.African study https://t.co/yNcADSA2FT

[Ryan McBride @rymcbr]

@MaverickNY Appreciate the rare combination of incisive analysis and good humor, Sally!

[Sally Church @MaverickNY]

Our latest oncology company interview has just posted. This one explores the bridge between preclinical and phase 1 R&D as a pipeline gets replenished with promising new compounds: https://t.co/bGAQhS3bG8

[Vas Narasimhan @VasNarasimhan]

Today’s encouraging news from Pfizer & BioNTech signals a possible breakthrough in combating COVID-19, which the world urgently needs. I commend the hard work of the researchers, scientists, clinicians & all those involved in bringing this forward quickly to address the pandemic

[Dr. Tom Frieden @DrTomFrieden]

Estimated cost of recent epidemics/pandemics:

SARS (2003) - $40 billion
H5N1 (2006) - $40 billion
H1N1 (2009) - $45 billion
Ebola (2014) - $55 billion
COVID-19 (2020) - $8.8 TRILLION

Investing in public health preparedness is FAR cheaper than the economic impact of a pandemic.

[Jay Bradner, M.D. @jaybradner]

As the pandemic heightened in China, Yan led a dedicated development team to respond to our current public health crisis. Their creativity & collaboration in the early phases of the pandemic helped us to prepare our continued support for patients enrolled in our #clinicaltrials.

[Vas Narasimhan @VasNarasimhan]

Especially in low- and lower middle–income countries, managing #COVID19 and the related symptoms of the virus remains a pressing challenge. With this new portfolio, we’re building on our previous actions to help combat the pandemic around the world.

[Luke Timmerman @ldtimmerman]

The Remdesivir Pricing Letter that Gilead Sciences Should Have Written. By @PeterKolchinsky https://t.co/LpY1hPU3OS

[Lisa Jarvis @lisamjarvis]

This pandemic has pushed the boundaries of how fast scientists can understand, track, and tackle a disease. Join me on June 25th for a conversation w/ @jaybradner & @davidrliu about how #COVID19 could change research. Register (free!) here: https://t.co/KsadMQryaN

[Novartis @Novartis]

Meet Florencia, a physician-scientist focused on infectious diseases. Florencia’s bringing her expertise to the fight against #COVID19, designing a large-scale trial to test the effectiveness of a potential treatment. #coronavirus

[Dan Nomura @DanNomura]

Happy to work together with a great team of ⁦@UCB_Chemistry ⁦@berkeleyMCB⁩ grad students, postdocs & ⁦@NovartisScience⁩ ⁦@jaybradner⁩ ⁦@ChemGenetics⁩ ⁦@Toste_Group⁩ ⁦@igisci⁩ to develop pan-coronavirus therapies! https://t.co/12Pf61KJJC